Skip to main content

Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion

  • Protocol
  • First Online:
Cancer Immunosurveillance

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1884))

Abstract

Cancer cells leaving the primary tumor immunosuppressive microenvironment become vulnerable to active immune surveillance and require mechanisms of immunoevasion to survive in the circulation. Studies have identified several pathways by which circulating tumor cells (CTCs) might escape the immune system/immunotherapy attack. The PD-1/PD-L1 axis is an immune checkpoint regulator, playing a major role in maintaining self-tolerance. It is now well recognized that tumor cells co-opt the PD-1/PD-L1 axis of immune regulation to interfere with cytotoxic T lymphocyte function. Transcriptional changes in CTCs, leading to the upregulation of PD-L1, might enable them to survive in circulation. Very recent data revealed a previously unappreciated role of epithelial-mesenchymal transition (EMT) in reprogramming the immune response in the local tumor microenvironment and a mutual regulation between EMT and immunoevasion is becoming apparent. In this chapter, we will describe in detail both EpCAM-dependent and -independent approaches that allow the identification of PD-L1 expression and EMT-like features in circulating tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847–856

    Article  CAS  Google Scholar 

  2. Remon J, Chaput N, Planchard D (2016) Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 28:122–129

    Article  CAS  Google Scholar 

  3. Buder A, Tomuta C, Filipits M (2016) The potential of liquid biopsies. Curr Opin Oncol 28:130–134

    Article  CAS  Google Scholar 

  4. Mazel M, Jacot W, Pantel K et al (2015) Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 9:1773–1782

    Article  CAS  Google Scholar 

  5. Nicolazzo C, Raimondi C, Mancini M et al (2016) Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep 6:31726

    Article  CAS  Google Scholar 

  6. Terry S, Savagner P, Ortiz-Cuaran S et al (2017) New insights into the role of EMT in tumor immune escape. Mol Oncol 11:824–846

    Article  Google Scholar 

  7. Raimondi C, Carpino G, Nicolazzo C et al (2017) PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system? OncoImmunology 6(12):e1315488. https://doi.org/10.1080/2162402X.2017.1315488

    Article  PubMed  PubMed Central  Google Scholar 

  8. Paoletti C, Li Y, Muñiz MC et al (2015) Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res 21:2771–2779

    Article  CAS  Google Scholar 

  9. Carpino G, Cardinale V, Renzi A et al (2015) Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis. J Hepatol 63:1220–1228

    Article  Google Scholar 

  10. Coumans F, Terstappen L (2015) Detection and characterization of circulating tumor cells by the cellsearch approach. Methods Mol Biol 1347:263–278

    Article  CAS  Google Scholar 

  11. Woititz CA (2008) Guideline for the use and optimization of user-defined markers. CellSearch®. https://www.cellsearchruo.com/sites/default/files/Guideline-for-Use-and-Optimization-of-User-Defined-Markers.pdf

  12. Nicolazzo C, Raimondi C, Francescangeli F et al (2017) EpCAM-expressing circulating tumor cells in colorectal cancer. Int J Biol Markers 32(4):e415–e420. https://doi.org/10.5301/ijbm.5000284

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Nicolazzo, C., Gradilone, A., Carpino, G., Gazzaniga, P., Raimondi, C. (2019). Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion. In: López-Soto, A., Folgueras, A. (eds) Cancer Immunosurveillance. Methods in Molecular Biology, vol 1884. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8885-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8885-3_17

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-8884-6

  • Online ISBN: 978-1-4939-8885-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics